NF-κB in carcinoma therapy and prevention
- 12 August 2008
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 12 (9) , 1109-1122
- https://doi.org/10.1517/14728222.12.9.1109
Abstract
Background: NF-κB includes a family of signal-activated transcription factors that normally regulate responses to injury and infection but which are aberrantly activated in many carcinomas. Objecti...Keywords
This publication has 120 references indexed in Scilit:
- Shared Principles in NF-κB SignalingCell, 2008
- The role of NF-κB in hepatocarcinogenesis: Promoter or suppressor?Journal of Hepatology, 2007
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Systemic Targeting Inhibitor of κB Kinase Inhibits Melanoma Tumor GrowthCancer Research, 2007
- Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activationProceedings of the National Academy of Sciences, 2006
- Protein Kinase Casein Kinase 2 Mediates Inhibitor-κB Kinase and Aberrant Nuclear Factor-κB Activation by Serum Factor(s) in Head and Neck Squamous Carcinoma CellsCancer Research, 2006
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerNew England Journal of Medicine, 2003
- NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaNature, 2003
- NF-κB, chemokine gene transcription and tumour growthNature Reviews Immunology, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999